Cargando…
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
BACKGROUND: We have previously investigated neoadjuvant ipilimumab (ipi) for patients with locally/regionally advanced melanoma. That initial assessment of peripheral blood mononuclear cells (PBMC) showed a significant increase in shared tumor associated antigen specific CD4(+) and CD8(+) T cell act...
Autores principales: | Retseck, Janet, VanderWeele, Robert, Lin, Hui-Min, Lin, Yan, Butterfield, Lisa H., Tarhini, Ahmad A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915044/ https://www.ncbi.nlm.nih.gov/pubmed/27330811 http://dx.doi.org/10.1186/s40425-016-0141-1 |
Ejemplares similares
-
Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
por: Najjar, Yana G., et al.
Publicado: (2017) -
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
por: Tarhini, Ahmad A., et al.
Publicado: (2014) -
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018) -
Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015) -
Circulating tumor cells capture disease evolution in advanced prostate cancer
por: Lack, Justin, et al.
Publicado: (2017)